Fusion

Fuzeon is an antiviral drug (anti-HIV drug) produced by the Swiss company Hoffmann-La Roche. The drug was developed for use in adults and adolescents with HIV infection or at risk of HIV infection. Fuzeon is a lyophilisate for the preparation of an injection solution containing the active substance Enfuvirtide at a dose of 90 mg/ml. The lyophilisate must be dissolved in sodium chloride injection (0.9% NaCl) or polysorbate solution before use. Pharmacological properties Enfuviratide stimulates the production of interferon gamma, interleukin-1 alpha, interleukin alpha 2 and beta, interferon-γ, fibroblast growth factor and other cytokines. Clinical studies have shown that taking fuzeon significantly improves the parameters of the patient’s immune system and increases the level of protective antibodies to HIV and strains of CD4+ lymphocytes. Increased levels of interleukin-1B and interferon gamma lead to an increase in the number of neutrophils and monocytes in the bone marrow during treatment with fuzeon, which is accompanied by a decrease in their number after using the drug. Indications for use The drug is indicated for use in patients undergoing combination antiretroviral therapy to reduce the risk of